Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,589 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Crossover Clear all
Completed Phase 3 Interventional Results available

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01724346
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Next-line ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
65 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
16
States / cities
Duarte, California • La Jolla, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

NCT02077803
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg, CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults

NCT05428761
View directory record Official record
Conditions
Dehydration, Rehydration, Exercise Performance, Exercise Recovery, Fluid Balance, Cognitive Performance
Interventions
TP1, TP2, Placebo
Other
Lead sponsor
Liquid I.V.
Other
Eligibility
18 Years to 49 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

NCT02650973
View directory record Official record
Conditions
Healthy
Interventions
CHS-1701, Pegfilgrastim
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
4
States / cities
Cypress, California • Cincinnati, Ohio • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Not applicable Interventional

A Preference Study of Two Pneumatic Compression Devices for Patients With Lower Limb Lymphedema

NCT05485454
View directory record Official record
Conditions
Lymphedema of Leg, Lymphedema, Lymphedema, Secondary, Lymphedema Primary, Lymphedema, Lower Limb
Interventions
Aria Health Aria Free, A Traditional PCD
Device
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation

NCT03359902
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Transcutaneous vagal nerve stimulation, Sham stimulation
Device
Lead sponsor
University of Florida
Other
Eligibility
60 Years to 89 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
3
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects

NCT01905553
View directory record Official record
Conditions
Healthy
Interventions
SSP-004184SS
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 22, 2026, 11:40 PM EDT
Terminated Phase 1Phase 2 Interventional

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

NCT00899977
View directory record Official record
Conditions
Refractory Hypertension
Interventions
Placebo, TC-5214
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Levetiracetam 1g Under Fasted Conditions

NCT00826722
View directory record Official record
Conditions
Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions

NCT00759902
View directory record Official record
Conditions
Healthy
Interventions
morphine sulfate extended-release capsules, KADIAN (morphine sulfate extended-release) capsules
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 22, 2026, 11:40 PM EDT
Terminated Not applicable Interventional

Impact of Exercise on Cognitive Impairment in End-Stage Renal Disease

NCT02145702
View directory record Official record
Conditions
Cognitive Impairment, End-Stage Renal Disease
Interventions
Aerobic Exercise, Standard Care Dialysis
Other · Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
20 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 22, 2026, 11:40 PM EDT
Terminated Phase 1 Interventional

Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease

NCT00739037
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo, PAZ-417
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2009 · Synced Oct 22, 2026, 11:40 PM EDT
Terminated Not applicable Interventional Results available

Oxytocin Add-on Study for Stable Anxiety Patients

NCT00989937
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

NCT00818870
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Omeprazole, Vecam
Drug
Lead sponsor
Vecta Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 4 Interventional Results available

Phase IV O2 Consumption Study in COPD Patients.

NCT02533505
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol, Matching Placebo pMDI 160/4.5 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Hartford, Connecticut • Boston, Massachusetts • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers

NCT03827629
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Treatment A: Naloxone Nasal Spray, Treatment B: Naloxone Nasal Spray, Treatment C: Naloxone HCL Intramuscular (IM) Injection
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects

NCT02785770
View directory record Official record
Conditions
Healthy
Interventions
PF-04447943, Placebo, Moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

NCT06247488
View directory record Official record
Conditions
Abuse Potential
Interventions
Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

NCT02893488
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG/ABC/3TC FDC DISPERSIBLE TABLET, EPZICOM (ABC/3TC), TIVICAY (DTG)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers

NCT04928703
View directory record Official record
Conditions
Healthy
Interventions
Ketamine
Drug
Lead sponsor
ERP Biomarker Qualification Consortium
Industry
Eligibility
21 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 22, 2026, 11:40 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

NCT00287066
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Human Insulin, Regular Human Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

NCT02562066
View directory record Official record
Conditions
Myasthenic Syndromes, Congenital
Interventions
amifampridine phosphate, Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

NCT00914641
View directory record Official record
Conditions
Thrombosis
Interventions
Apixaban IR, Apixaban MR1, Apixaban MR2, Apixaban MR3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 22, 2026, 11:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

NCT00803686
View directory record Official record
Conditions
Phase 1 Pharmacodynamic Study
Interventions
Oral rsCT tablet, Oral Placebo Tablet, Fortical (rsCT) nasal spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 22, 2026, 11:40 PM EDT